Orient EuroPharma (4120) Fundamentals 2026 — Revenue Analysis | SniperIQ
Orient EuroPharma (4120) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT$4.0B, trading at NT$45.90 on the TWO. This SniperIQ fundamentals page covers Orient EuroPharma's valuation, profitability (net margin -8.7%), revenue (NT$4.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Orient EuroPharma's market cap?
Orient EuroPharma (4120) has a market capitalization of approximately NT$4.0B, trading at NT$45.90 on the TWO. Market cap moves with the live share price.
What is Orient EuroPharma's P/E ratio?
Orient EuroPharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Orient EuroPharma?
Orient EuroPharma runs a net profit margin of -8.7%, a gross margin of 48.2%, and an operating margin of -4.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Orient EuroPharma generate?
Orient EuroPharma reported revenue of NT$4.6B for fiscal year 2025, with net income of -NT$567M and earnings per share (EPS) of -6.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Orient EuroPharma pay a dividend?
Orient EuroPharma offers a trailing dividend yield of about 8.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Orient EuroPharma financially healthy?
Orient EuroPharma carries a debt-to-equity ratio of 0.59x and a current ratio of 1.38x, with a market beta of 0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Orient EuroPharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Orient EuroPharma (4120) the key facts are: market cap NT$4.0B, revenue NT$4.6B, 52-week range 42.6-57.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Orient EuroPharma's full fundamentals live
Get Orient EuroPharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.